Health Canada has authorized Eli Lilly’s Foundayo, a daily GLP-1 pill for weight loss, giving eligible adults in Canada an oral alternative to weekly injections. The authorization was granted Nov. 13, with the company expecting pharmacy availability in January, according to reporting by Nicole Ireland of The Canadian Press, published by Global News.
Foundayo is approved for adults with obesity and for adults who are overweight and have at least one related medical condition, such as high blood pressure or sleep apnea. Beyond promoting and maintaining weight loss, the medication is also authorized to help treat Type 2 diabetes.
Its active ingredient, orforglipron, is a non-peptide GLP-1 receptor agonist. That distinguishes it from semaglutide, used in Novo Nordisk’s Ozempic and Wegovy, and tirzepatide, used in Eli Lilly’s Mounjaro and Zepbound.
Dr. Ehud Ur, a Vancouver endocrinologist who is not associated with either company, told The Canadian Press that orforglipron’s smaller molecular size allows it to be taken orally and absorbed without being broken down by the digestive system.
Ur said his decision on whether to prescribe Foundayo would depend on the patient. He is still awaiting clinical trial results on whether orforglipron offers a cardiovascular benefit like those associated with semaglutide and tirzepatide.
The most common side effects of GLP-1 medications, whether taken orally or by injection, include gastrointestinal problems such as nausea and vomiting.
Canada already has another GLP-1 pill on the market: Novo Nordisk’s Rybelsus. However, its authorization is for Type 2 diabetes management, not weight loss. Foundayo’s approval therefore expands the oral treatment options available specifically for weight management.
Another option could follow. Novo Nordisk’s Wegovy pill is awaiting Health Canada approval, while both it and Foundayo are already approved and available in the United States.
The Wegovy pill uses semaglutide, a larger peptide molecule, together with an ingredient called salcaprozate sodium. Novo Nordisk spokesperson Kate Hanna said that ingredient temporarily makes the surrounding area less acidic and helps the medication pass through the stomach lining into the bloodstream.




Leave a comment
Join the discussion. Please follow our Community Standards.
Sign in or create an account to leave a comment.
Choose your public display name before submitting. Your email address stays private.
No published comments yet.